Company intelligence / Profile preview

Tegmine Therapeutics

South San Francisco, California, United Statestegminetx.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Tegmine Therapeutics is developing antibody-based therapies targeting unique glycoproteins in solid tumors using its proprietary TegMiner™ discovery platform. The company is currently in the pre-clinical stage and aims to enhance efficacy while minimizing toxic side effects. No clinical results have been published yet.[1][2][4]

Therapeutic areas: Oncology
Modalities: Monoclonal antibodies (mAbs)Antibody-drug conjugates (ADCs)
Industry: Biotech

Beyond the preview

Go deeper on Tegmine Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tegmine Therapeutics.

Explore the full profile